This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.


GATC to be part of Eurofins Group

Constance, Germany, June 2nd, 2017: GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017 to create the leading company in the worldwide sequencing market.

Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, announces that it has signed an agreement to acquire GATC Biotech AG (“GATC”), one of Europe´s specialists in DNA sequencing. The transaction is expected to close in July, subject to the fulfilment of customary closing conditions.

Founded in 1990, GATC has achieved a strong recognition for DNA and RNA sequencing, as well as bioinformatics in Europe. The company employs 140 staff across 2 sites, and serves over 10,000 institutional and academic customers, generating annual revenues of about EUR 20m. As one of the larger players in Custom and Next Generation Sequencing, GATC has built a reputation for innovative, internally-developed applications, as well as industry-leading turn-around time (TAT). The acquisition should therefore further reinforce Eurofins' footprint in DNA sequencing, and strengthen the Group's technological platform supporting its genetic testing innovations.

Source: GATC



Roche launches AVENIO ctDNA Analysis Kits for Oncology Research

Basel, 08 May 2017 
Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits, a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit. The kits include all reagents, bioinformatics and software to make ctDNA testing accessible to all NGS laboratories.

“We are pleased to introduce these state-of-the-art AVENIO ctDNA Analysis Kits1,2,3 that combine the convenience of liquid biopsy with the power of next generation sequencing,” said Roland Diggelmann, Chief Executive Officer, Roche Diagnostics. “Roche believes the AVENIO ctDNA assays can help researchers around the world advance personalized oncology by enabling them to carry out their own testing.”

The AVENIO ctDNA Analysis Kits are aligned with NCCN guidelines to support oncology research4. The kits detect all four mutation classes with high sensitivity3. With three different kits available, researchers can profile the genomic complexities of different cancer stages and tumor types, obtaining results in five days.
“As a cancer researcher, I see a tremendous advantage to using the AVENIO ctDNA Analysis Kits”, said Peter Meldgaard, MD, PhD, Associate Professor of Oncology at Aarhus University in Denmark. “Cancer is a highly complex disease, so the ability to obtain a complete and accurate genomic profile of malignant tumors and monitor changes in tumor burden is invaluable.”

Source: Roche, Basel



Launch of the GridION X5 

Tue 14th March 2017, Oxford Nanopore Technologies announced the launch of the GridION X5, a new system that can drive up to five MinION Flow Cells and process all the data produced within a single benchtop device. GridION X5 can be used to offer nanopore sequencing as a service.

As the community of MinION users starts to reap the benefits of these releases, we are also preparing to release PromethION Flow Cells that are designed to yield up to six times the Gb of a MinION Flow Cell , so that the entire PromethION can yield Terabases of data. GridION fills a gap between MinION and PromethION.

The performance of MinION has improved 40-fold since its first introduction and data processing requirements at the newest high throughputs are now beginning to challenge the average PC. The GridION will adapt the MinION technology into a small benchtop production sequencer with the advantage of full on-board compute capable of generating 100GB of data over 48 hours.

This capacity is completely controlled by the user. All five flow cells can be dedicated to one project, or each flow cell can be used to sequence different samples. As with all nanopore sequencing there is no fixed run time.

Source: Oxford Nanopore Technologies



CENTOGENE extends its genetic test portfolio for rare diseases

16 January 2017, Centogene, Rostock/ Germany

CENTOGENE is a worldwide leader in the field of genetic diagnostics for rare hereditary diseases. Testing samples from over 110 different countries allows CENTOGENE a unique insight into the epidemiological basis of hereditary disorders, which is crucial for interpreting results and transform it into medical reports.

CENTOGENE has recently added numerous single gene tests and next generation sequencing (NGS) panels to its portfolio. Our NGS panel compositions always reflect the clinical relevance to the specific disease phenotype, transforming genetic data into actionable medical decisions.

New added single gene tests are for Metabolic Diseases, Neurological Diseases, Bone, Skin and Immune Diseases, Cardiological and Lung Diseases, and for Haematological Diseases.

New NGS panels are for Neurological Diseases, Ophthalmological Diseases, Bone, Skin and Immune Diseases, Cardiological and Lung Diseases, Vascular Diseases, and for Malformation and Retardation Syndromes.
For more information visit the website of Centogene



Illumina, NRGene Collaborate to Accelerate Development of New Molecular Breeding Tools for Cattle

SAN DIEGO & NESS ZIONA, Israel--(BUSINESS WIRE)--Jan. 12, 2017-- Illumina, Inc. (NASDAQ: ILMN), the global leader in next-generation sequencing technology, and NRGene, a globally recognized leader in genome assembly and analysis, today announced a collaboration to develop new molecular breeding tools for cattle. As a first step, the companies also announced the completion of a high quality genome assembly of the Nellore cattle in conjunction with researchers at the Universidade Estadual Paulista in Brazil.

The companies will work together to sequence and assemble additional cattle individuals from different breeds to accelerate knowledge of genetic variation across all cattle breeds. This information will aid in the development of new commercial tools that can be used for genomic selection and other genomic technologies in cattle, helping to accelerate breeding programs to enhance global food (meat and milk) production efforts.

Source: Illumina


Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases

SAN DIEGO & HERCULES, Calif.--(BUSINESS WIRE)--Jan. 9, 2017-- Illumina, Inc. (NASDAQ:ILMN) and Bio-Rad Laboratories, Inc. (NYSE:BIO) (NYSE:BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.

The solution comprises the ddSEQ™ Single-Cell Isolator and SureCell™ WTA 3’ Library Prep Kit. Bio-Rad’s best-in-class droplet partitioning technology, Droplet Digital™ technology, is used to isolate and barcode single cells for downstream sequencing on many of Illumina’s leading NGS instruments. The comprehensive workflow solution includes primary and secondary data analysis conducted via the BaseSpace® Informatics Suite, Illumina’s cloud-based genomics computing environment, and tertiary data analysis and visualization with SeqGeq™ from FlowJo, LLC, the market leader in flow cytometry analysis.

Source: Illumina


Illumina Introduces the NovaSeq Series—a New Architecture Designed to Usher in the $100 Genome

SAN DIEGO--(BUSINESS WIRE)--Jan. 9, 2017-- Illumina, Inc. (NASDAQ: ILMN), the global leader in next-generation sequencing technology, today introduced the NovaSeqTM Series, a new and scalable sequencing architecture expected one day to enable a $100 genome. Unveiled at the J.P. Morgan Healthcare Conference, this platform redefines high throughput sequencing with unrivaled throughput, ease of use, low per sample costs, and unmatched flexibility.

NovaSeq is the most powerful sequencer Illumina has ever launched and will open new horizons for more highly powered experiments at the depth required to discover rare genetic variants. It was designed from the ground up to allow a broad set of researchers to access next-generation sequencing technology and more easily conduct large-scale genomics projects with greater sample volumes, or more breadth and depth in the genome. In addition to a single instrument capable of sequencing from three to 48 human whole genomes per run, the NovaSeq Systems will open up new markets by making routine a wide range of applications from ultra-deep sequencing of matched tumor-normal pairs, to large-scale variant discovery studies associated with complex diseases, and low-pass sequencing of seed banks to select for specific traits.

Source: Illumina


Cancer Genetics, Inc. Launches Focus::Renal™, a Unique, Comprehensive and Highly Sensitive Next Generation Sequencing (NGS) Panel for Enabling Precision and Personalized Medicine in Renal Cancers

Wednesday, November 2nd, 2016 
Rutherford, N.J., November 2, 2016 – Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today the successful CLIA validation and approval of its next generation sequencing (NGS) assay that enables an era of precision medicine for renal cancers, Focus::Renal™. Focus::Renal™, a highly-sensitive NGS panel, detects mutations of 76 renal cancer-related genes, as well as genome-wide copy number changes, and critical single nucleotide polymorphisms (SNPs), all in a single test, that enable precision diagnosis, prognosis, and therapy selection for renal cancer patients.


Focus::Renal™ is a unique NGS panel, developed by CGI in collaboration with leading cancer centers and academic institutions, including MSKCC, Cleveland Clinic, Huntsman Cancer Center at University of Utah, and University Hospital of Paris. Focus::Renal™ is a comprehensive and accurate genomic profiling tool covering the majority of renal cancer markers and pathways. Focus::Renal™ is designed based on the most current scientific literature, TCGA genomic data, and in-house findings as a result of collaborations with leading research institutions, and has undergone multiple independent validations using samples from over 500 patients. The test can be performed on a wide variety of patient specimen types, such as needle biopsies, fine-needle aspirates, and resected specimens using both formalin-fixed paraffin-embedded (FFPE) and fresh/fresh-frozen specimens, including the ones with minimal starting material, giving clinicians a choice on how to incorporate the test into their diagnostic workflow. The Focus::Renal™ NGS panel can be utilized to distinguish among the dominant 3 malignant and 1 benign renal cancer subtypes, which is today largely driven by morphological and immunohistochemical review.